ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

On-and-off fasting helps fight obesity, study finds

Can Pomegranates Slow Aging?

Calorie restriction promotes longevity through effects on mitochondrial network

Discover Why Ashwagandha Can Be Used for Stress and Anxiety

Lower magnesium levels linked with increased mortality risk during up to 40 years of follow-up

A spoonful of oil: Fats and oils help to unlock full nutritional benefits of veggies, study suggests

Higher resveratrol dose linked to lower glucose levels in type 2 diabetics

How Can You Benefit From Vitamin B12?

Drug can dramatically reduce weight of people with obesity

What Is Bitter Orange?

 
Print Page
Email Article

Xyrem Clinical Trial for Fibromyalgia Patient Enrollment Begins

  [ 676 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 9, 2004


Orphan Medical, Inc. (Nasdaq:ORPH) announced today [June 30, 2004] that it has initiated patient enrollment in a clinical trial designed to evaluate Xyrem(R) (sodium oxybate) oral solution in the treatment of fibromyalgia. The protocol calls for 150 patients to complete a three-month trial with an eight-week active treatment period that will assess the impact of Xyrem on the symptoms of fibromyalgia, including the sleep disturbance that typically accompanies fibromyalgia.

After a washout period, patients will be assigned in a randomized, blinded manner to one of two active Xyrem dosing arms or to a placebo arm. The Company expects that initial data from the trial will be available in mid-2005. Trial sites will be located throughout the United States and Canada with approximately 20 participating centers. "This trial is an important step in evaluating the potential of Xyrem in the treatment of fibromyalgia and we will work to complete this trial quickly, and if the outcome is positive, we will work with the FDA to aggressively move forward on a program for development," said John Bullion, Orphan Medical Chief Executive Officer. "There is no currently approved treatment for fibromyalgia syndrome and we believe that Xyrem could play an important role in the treatment of this substantial patient population."

Fibromyalgia is a chronic condition that is estimated to affect over four million individuals in the United States and represents a market opportunity in excess of a billion dollars per year. The disease is characterized by widespread muscle pain and stiffness and affects women three times more often than men. Other symptoms include persistent fatigue, headaches, cognitive or memory impairment, morning stiffness and non-restorative sleep.

Orphan Medical acquires, develops, and markets pharmaceuticals of high medical value for inadequately treated and uncommon CNS diseases treated by specialist physicians. The lead product for the Company is Xyrem which is the first and only approved treatment for cataplexy associated with narcolepsy. Xyrem is also being assessed as a treatment for the full range of narcolepsy symptoms including excessive daytime sleepiness. Orphan Medical's pipeline includes development stage products for fibromyalgia and pain. Orphan Medical's Internet Web site address is www.orphan.com

The information in this press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results to differ materially from the Company's assumptions and expectations. These are set forth in the cautionary statements included in Orphan Medical's most recent Form 10-Q or Form 10-K filed with the Securities and Exchange Commission. (These documents can be accessed through the Orphan Medical Web site at http://www.orphan.com). All forward-looking statements are qualified by, and should be considered in conjunction with, such cautionary statements. Contact: Orphan Medical, Inc., Minneapolis
Tim McGrath, 952-513-6900
or
David Folkens, 952-513-6994 Source: Business Wire/PR Newswire



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Safely Burn Away Body Fat Safely Burn Away Body Fat
Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map